Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PNB-New #3
- Development stage
- Preclinical
- Lead developer
- Peptinovo Biopharma
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
PNB-New #3 is a preclinical-stage nanoparticle formulation developed by Peptinovo Biopharma using its proprietary PALM™ (Peptide-Amphiphile Lipid Micelle) technology platform. The drug consists of the chemotherapy agent gemcitabine, a nucleoside analog, encapsulated within PALM™ nanoparticles designed for targeted delivery to tumor cells. Gemcitabine acts as a pyrimidine antimetabolite that inhibits DNA synthesis by replacing cytidine during DNA replication and inhibiting ribonucleotide reductase, leading to apoptosis. The PALM™ delivery system is engineered to improve the therapeutic index of gemcitabine by enhancing tumor accumulation and reducing systemic toxicity through its nanoparticle carrier properties.
- Other names
- PALM-gemcitabine
02
Targets
RNR (Ribonucleotide reductase)DNA
Beyond the preview
Go deeper on PNB-New #3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PNB-New #3.